Showing 1581-1590 of 1732 results for "".
- Long-Term Freedom from Seizure With Perampanel Treatmenthttps://practicalneurology.com/news/long-term-freedom-from-seizure-with-perampanel-treatment/2469455/In a post-hoc analysis, of the phase 3 FREEDOM study (NCT03201900), 62.5% of individuals treated with 4 to 8 mg/day of perampanel (Fycompa, Eisai Inc, Woodcliff Lake, NJ) achieved seizure freedom for 1 year. Participants in the study w
- Laser Thermal Ablation Therapy Brings Seizure Freedom to 54% of Children Treatedhttps://practicalneurology.com/news/laser-thermal-ablation-therapy-brings-seizure-freedom-to-54-of-children-treated/2469450/A new study being presented virtually at American Epilepsy Society AES2020 showed MRI-guided laser interstitial thermal therapy (MR-LITT) in children with medically refractory epilepsy, achieved seizure freedom for 54% 1 year after the procedure. Children treated (n=182) were age 14 months of age
- Minimally Invasive Laser Ablation Epilepsy Surgery Provides 64% Treated With Seizure Freedomhttps://practicalneurology.com/news/minimally-invasive-laser-ablation-epilepsy-surgery-provides-64-treated-with-seizure-freedom/2469423/Results published in Epilepsy Research, showed minimally invasive laser ablation epilepsy surgery (NeuroBlate System; Monteris Medical, Plymouth, MN) resulted in seizure freedom for 64% of those treated (n=42) measured 12 months after the procedure. Individuals who had the procedure had medically
- Lasmiditan Treatment Provides Pain Freedom At 2 Hours in at Least 2 of 3 Migraine Attacks in New Phase 3 Studyhttps://practicalneurology.com/news/lasmiditan-treatment-provides-pain-freedom-at-2-hours-in-at-least-2-of-3-migraine-attacks-in-new-phase-3-study/2469397/In the phase 3 CENTURION study, participants treated with lasmiditan (Reyvow; Eli Lilly, Indianapolis, IN) for migraine attacks, doses of 100 mg or 200 mg, had 3.8 and 7.2 times greater odds of achieving pain freedom at 2 hours post treatment compared with placebo in at least 2 out of 3 attacks.&
- Investigation of Foralumab for Alzheimer Disease Treatment Will Continue to Phase 2https://practicalneurology.com/news/investigation-of-foralumab-for-alzheimer-disease-treatment-will-continue-to-phase-2/2469286/Nasally administered foralumab (Tiziana Life Sciences, New York, NY) has showed delays in disease processes underlying the progression of Alzheimer disease (AD) in animal models . Based on those results, the investigation of foralumab for AD will continue to phase 2 clinical trials. Foralum
- Shine Forward with Dravet, Support Resource for Parents of Children Living with Dravet Syndrome Launchedhttps://practicalneurology.com/news/shine-forward-with-dravet-support-resource-for-parents-of-children-living-with-dravet-syndrome-launched/2469264/A new resource for parents of children with Dravet syndrome (DS), Shine Forward with Dravethas been launched by pharmaceutical company Zogenix (Emeryville, CA). The website includes a unique set of online tips, tools, and advice from families and is designed to inspire deeper connections between
- Once-Nightly Extended Release Formulation of Sodium Oxybate Shows Efficacy for Excessive Daytime Sleepiness and Cataplexyhttps://practicalneurology.com/news/once-nightly-extended-release-formulation-of-sodium-oxybate-shows-efficacy-for-excessive-daytime-sleepiness-and-cataplexy/2469241/A phase 3 clinical trial shows that an investigational extended release formulation of sodium oxybate (FT218; Avadel Pharmaceuticals, Dublin, Ireland) increased wakefulness and decreased cataplexy. This unique formulation of sodium oxybate uses a micropump technology to allow for once nightly dos
- Ubrogepant Provides Freedom from Pain for Acute Treatment of Migraineshttps://practicalneurology.com/news/ubrogepant-treatment-of-migraine-provides-freedom-from-pain-for-acute-treatment-of-migraine/2469102/The results from the phase 3 ACHIEVE I trial (NCT02828020) evaluated the efficacy, safety, and tolerability of ubrogepant (Allergan; Madison, NJ). Acute treatment of migraine with ubrogepant provided higher rates of pain freedom and fre
- Generic Fingolimod for Relapsing Forms of Multiple Sclerosis Approved by the FDAhttps://practicalneurology.com/news/generic-fingolimod-for-relapsing-forms-of-multiple-sclerosis-approved-by-the-fda/2469094/The Food and Drug Administration (FDA) has approved 3 applications for the first generics of fingolimod (Gilenya; Novartis AG, Basel, Switzerland) for treating relapsing forms of multiple sclerosis (MS) in adult patients. Fingolimod is a sphingosine 1-phosphate receptor modulator indica
- Edaravone Oral Formulation Being Tested in Phase 3 Trial for ALShttps://practicalneurology.com/news/edaravone-oral-formulation-being-tested-in-phase-3-trial-for-als/2469086/The first participant has been enrolled in a global phase 3 study (NCT04165824) of an oral suspension formulation of edaravone (Radicava; Mitsubishi Tanabe Pharma, Jersey City, NJ) for potential treatment of amyotrophic lateral scleros